Session: SUN 257-280-Disorders of Vitamin D Metabolism & Action
Poster Board SUN-261
Methods: A total of 499 randomly selected subjects divided into 2 groups [non-DMT2 Controls=151; DMT2=348]. All DMT2 patients were given 2000 IU vitamin D3 daily, while the control group received none but were advised to increase sun exposure. Anthropometrics, glucose, lipid profile and 25-hydroxyvitamin D were measured at baseline, and at 6 and 12 months.
Results: Circulating 25-hydroxyvitamin D concentrations improved in all patient groups and the controls. The metformin group showed the highest change in circulating vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as compared to baseline (p < 0.001). Significant improvements were observed in systolic blood pressure, total- and HDL-cholesterol in male patients on insulin + oral agents after vitamin D supplementation (p-values<0.05). Significant decreases in triglycerides were also observed in the rosiglitazone and insulin + oral hypoglycemic agent groups both at 6 and 12 months of supplementation (p-values<0.001).
Conclusion: Vitamin D therapy at a dose of 2000 IU appears to alter cardiovascular disease risk factors under particular anti-diabetic regimens. Effects on well-being and other parameters need further study.
Nothing to Disclose: KA, NMA, SS, AA, OM, MSA, YA, SK, GPC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters